The role of procoagulants and anticoagulants in the development of venous thromboembolism

Thrombosis Research

Volumn 123, Issue SUPPL. 4, 2009, Pages

  Bertina, Rogier M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anticoagulants; Procoagulants; Venous thrombosis

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRIN; FIBRINOGEN; PROCOAGULANT; PROTEIN C; PROTEIN S; THROMBIN; THROMBOMODULIN; THROMBOPLASTIN;

ANTITHROMBIN DEFICIENCY; ARTICLE; ENZYME ACTIVITY; HEMOSTASIS; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; THROMBOGENESIS; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANIMALS; BLOOD COAGULATION; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; FIBRIN; HUMANS; KINETICS; RISK FACTORS; THROMBIN; THROMBOPLASTIN; VENOUS THROMBOEMBOLISM;

EID: 62249090190     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(09)70142-2     Document Type: Article

References (32)

1. Crawley J.T., and Lane D.A. The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 28 (2008) 233-242
2. Hackeng T.M., Seré K.M., Tans G., and Rosing J. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci USA 103 (2006) 3106-3111
3. Dahm A., van Hylckama Vlieg A., Bendz B., Rosendaal F., Bertina R.M., and Sandset P.M. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 101 (2003) 4387-4392
4. Jesty J., and Beltrami E. Positive feedbacks of coagulation. Their role in threshold regulation. Arterioscler Thromb Vasc Biol 25 (2005) 2463-2469
5. Van Boven H.H., and Lane D.A. Antithrombin and its inherited deficiency states. Semin Hematol 34 (1997) 188-204
6. Mann K.G., Butenas S., and Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol 23 (2003) 17-25
7. Gailani D., and Broze G.J. Factor XI activation in a revised model of blood coagulation. Science 253 (1991) 909-912
8. Pedicord D.L., Seiffert D., and Blat Y. Feedback activation of factor XI by thrombin does not occur in plasma. Proc Natl Acad Sci USA 104 (2007) 12855-12860
9. Mosesson M.W. Update on antithrombin I (fibrin). Thromb Haemost 98 (2007) 105-108
10. Lovely R.S., Boshkov L.K., Marzec U.M., Hanson S.R., and Farrell D.H. Fibrinogen gamma chain carboxyterminal peptide selectively inhibits the intrinsic coagulation pathway. Br J Haematol 139 (2007) 494-503
11. Lancellotti S., Rutella S., De Filippis V., Pozzi N., Rocca B., and De Cristofaro R. The fibrinogen elongated g-chain inhibits thrombin-induced platelet response, hindering the interaction with different receptors. J Biol Chem 283 (2008) 30193-30204
12. Koster T., Blann A.D., Briët E., Vandenbroucke J.P., and Rosendaal F.R. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345 (1995) 152-155
13. Van Hylckama Vlieg A., van der Linden I.K., Bertina R.M., and Rosendaal F.R. High levels of factor IX increase the risk of venous thrombosis. Blood 95 (2000) 3678-3682
14. Meijers J.C., Tekelenburg W.L., Bouma B.N., Bertina R.M., and Rosendaal F.R. High levels of coagulation factor XI as a risk factor of venous thrombosis. N Engl J Med 342 (2000) 696-701
15. Nossent A.Y., Eikenboom J.C.J., and Bertina R.M. Plasma coagulation factor levels in venous thrombosis. Semin Hematol 44 (2007) 77-84
16. Morelli V.M., de Visser M.C.H., Vos H.L., Bertina R.M., and Rosendaal F.R. ABO blood group genotypes and the risk of venous thrombosis: effect of factor V Leiden. J Thromb Haemost 3 (2005) 183-185
17. Poort S.R., Rosendaal F.R., Reitsma P.H., and Bertina R.M. A common genetic variation in the 3 -untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88 (1996) 3698-3703
18. Uitte de Willige S., Rietveld I., de Visser M.C.H., Vos H.L., and Bertina R.M. Polymorphism 10034C>T is located in a region regulating polyadenylation of FGG transcripts and influences the fibrinogen g /gA ratio. J Thromb Haemost 5 (2007) 1243-1249
19. Uitte de Willige S., de Visser M.C.H., Houwing-Duistermaat J.J., Rosendaal F.R., Vos H.L., and Bertina R.M. Genetic variation in the fibrinogen gamma gene increases the risk of venous thrombosis by reducing plasma fibrinogen g levels. Blood 106 (2005) 4176-4183
20. Kalafatis M., Rand M.D., and Mann K.G. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 269 (1994) 31869-31880
21. R506Q by activated protein C. J Biol Chem 270 (1995) 21158-21166
22. R506Q by activated protein C. J Biol Chem 270 (1995) 27852-27858
23. Tran S., Norstrøm, and Dahlbäck B. Effects of prothombin on the individual activated protein C-mediated cleavages of coagulation factor Va. J Biol Chem 81 (2008) 6648-6655
24. Thorelli E., Kaufman R.J., and Dahlbäck B. Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V. Blood 93 (1999) 2552-2558
25. Aiach M., Borgel D., Gaussem P., Emmerich J., Alhenc-Gelas M., and Gandrille S. Protein C and protein S deficiencies. Sem Hematol 34 (1997) 205-217
26. Dahlbäck B., Carlsson M., and Svensson P.J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 90 (1993) 1004-1008
27. Koster T., Rosendaal F.R., de Ronde H., Briët E., Vandenbroucke J.P., and Bertina R.M. Venous thrombosis due to poor anticoagulant response to activated protein C: the Leiden Thrombophilia Study. Lancet 342 (1993) 1503-1506
28. Bertina R.M., Koeleman B.P.C., Koster T., Rosendaal F.R., Dirven R.J., de Ronde H., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369 (1994) 64-67
29. De Visser M.C.H., Rosendaal F.R., and Bertina R.M. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 93 (1999) 1271-1276
30. De Visser M.C.H., van Hylckama Vlieg A., Tans G., Rosing J., Dahm A., Sandset P.M., et al. Determinants of the APTT- and ETP-based APC sensitivity tests. J Thromb Haemost 3 (2005) 1488-1494
31. Falati S., Gross P., Merrill-Skoloff G., Furie B.C., and Furie C. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med 8 (2002) 1175-1180
32. Tesselaar M., Romijn F.P.H.T.M., van der Linden I.K., Prins F.A., Bertina R.M., and Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis. J Thromb Haemost 5 (2007) 520-527